We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Two Drugs Slash Risk of Stroke Recurrence

By HospiMedica staff writers
Posted on 12 Jul 2001
A landmark six-year study has discovered that two drugs for lowering blood pressure, even when administered to stroke patients who did not have high blood pressure, reduced the risk of further strokes and heart attacks by 25-50%. More...
The results of the study, conducted by an independent group of medical researchers, were presented at the European Society of Hypertension (ESH) in Milan (Italy).

The study involved 6,000 high-risk stroke sufferers in 172 hospitals, who were treated with two blood-pressure drugs (perindopril and indapamide) over a period of five years. One in every ten (10%) avoided either death, heart attack, or further during that period. The drugs also reduced the risk of serious complications of stroke such as disability and dementia. According to world health statistics, about 20% of high-risk stroke patients suffer another stroke or heart attack within five years. More than two-thirds of all strokes occur in people who do not have high blood pressure as defined by the World Health Organization (WHO).

Currently, blood pressure drugs are given mainly to a minority of people who suffer a stroke or transient ischemic attack. Aspirin is the only treatment given widely to patients after stroke, but it is not suitable for people who have suffered some particularly dangerous types of stroke, such as cerebral hemorrhage. In the study, perindopril, an ACE (angiotensin-converting enzyme) inhibitor, and indapamide together reduced the risk of stroke by 75% among patients who had previously suffered a cerebral hemorrhage.

"There is a strong case for making these drugs available to most stroke patients, irrespective of their age and blood pressure and irrespective of the other treatments they may be receiving,” said Professor Stephen MacMahon, of the University of Sydney (Australia), one of the study's organizers. "The benefits are unusually large and occur in a wide range of patients. There were very few side effects.”




Related Links:
Univ. of Sydney

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.